Next Article in Journal
A Highly Efficient and Reusable Palladium(II)/Cationic 2,2’-Bipyridyl-Catalyzed Stille Coupling in Water
Next Article in Special Issue
Combating Ebola with Repurposed Therapeutics Using the CANDO Platform
Previous Article in Journal
Synthesis and Cytotoxic Activity on Human Cancer Cells of Novel Isoquinolinequinone–Amino Acid Derivatives
Previous Article in Special Issue
Boronic Acid Group: A Cumbersome False Negative Case in the Process of Drug Design
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 21
Issue 9
10.3390/molecules21091193
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

NO-Releasing Enmein-Type Diterpenoid Derivatives with Selective Antiproliferative Activity and Effects on Apoptosis-Related Proteins

by
Dahong Li
1,
Xu Hu
1,
Tong Han
1,
Jie Liao
1,
Wei Xiao
2,*,
Shengtao Xu
3,
Zhanlin Li
1,
Zhenzhong Wang
2,
Huiming Hua
1,* and
Jinyi Xu
3,*
1
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China
2
State Key Laboratory of New-Tech for Chinese Medicine Pharmaceutical Processes, National Post-Doctoral Research Workstation, Jiangsu Kanion Pharmaceutical Co. Ltd., Lianyungang 222001, China
3
State Key Laboratory of Natural Medicines, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
*
Authors to whom correspondence should be addressed.
Molecules 2016, 21(9), 1193; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules21091193
Submission received: 12 July 2016 / Revised: 23 August 2016 / Accepted: 2 September 2016 / Published: 8 September 2016
(This article belongs to the Special Issue Drug Design and Discovery: Principles and Applications)
Browse Figures
Versions Notes

Abstract

:
A series of nine enmein-type ent-kaurane diterpenoid and furoxan-based nitric oxide (NO) donor hybrids (10a–i) were designed and synthesized from commercially available oridonin (1). These hybrids were evaluated for their antiproliferative activity against Bel-7402, K562, MGC-803, and CaEs-17 human cancer cell lines and L-02 normal liver cells. The antiproliferative activity against tumor cells was stronger than the lead compound 1 and parent molecule 9 in most cases. Especially, compound 10f showed the strongest activity against human hepatocarcinoma Bel-7402 cell line with an IC50 of 0.81 μM and could also release 33.7 μmol/L NO at the time point of 60 min. Compounds 10a–i also showed cytotoxic selectivity between tumor and normal liver cells with IC50 ranging from 22.1 to 33.9 μM. Furthermore, the apoptotic properties on Bel-7402 cells revealed that 10f could induce S phase cell cycle arrest and apoptosis at low micromolar concentrations. The effects of 10f on apoptosis-related proteins were also investigated. The potent antiproliferative activities and mechanistic studies warrant further preclinical investigations.

1. Introduction

Natural products and natural product structures continue to play a highly significant role in the drug discovery and development process, especially in the case of antitumor drugs [1]. Diterpenoids, especially ent-kaurane diterpenoids, are well known to produce bioactive molecules [2]. Among these, enmein-type 6,7-seco-ent-kaurane diterpenoids have unique chemical skeletons and exhibit significant activities (Figure 1) [3,4,5]. These natural enmein-type ent-kaurane diterpenoids with a lot of stereogenic centers and complex ring systems have attracted much attention [6,7,8,9,10,11,12,13,14,15]. Natural sources cannot afford large compound supply for structure modification. We have found a convenient and feasible method to construct the skeleton of enmein-type 6,7-seco-ent-kaurane diterpenoid from natural oridonin [9]. Further investigation in the field of medicinal chemistry is still in urgent need.
Nitric oxide (NO), one of the simplest, odorless, colorless, highly reactive, and biological molecules in nature, is a free radical and a key mediator involved in diverse physiological and pathological processes [16,17,18,19,20]. NO-donating compounds have recently come into focus for the treatment of tumors because NO plays a central role in cell regulatory pathways and is a key signaling molecule involved in the death and apoptosis of tumor cells [21,22,23,24,25,26,27,28,29,30,31,32]. Generally, high levels of NO (above 400 nM [33]) produced from NO donors can induce apoptosis, inhibit metastasis of tumor cells, and sensitize tumor cells to radiation, immunotherapy, and chemotherapy. Some synthesized NO-releasing compounds have already shown antitumor activity against human carcinoma cells in vitro and in vivo [21,22,23,24,25,26,27,28,29,30,31,32]. Due to the highly reactive nature of NO, it is difficult to predict its biological effects on a given system from single doses even if provided by the longer action of inducible nitric oxide synthase (iNOS). High concentrations of NO can be generated not only by iNOS, stimulated by cytokines, but also effectively by NO donors. Thus, NO donors, capable of producing a sustained release with a wide range of half-time lives and predictable estimated doses, have become useful tools to study the biological properties of NO in cells and in vivo models of carcinogenesis [34]. Furoxans are stable and represent an important class of NO donors, which can produce high levels of NO in vitro and inhibit the growth of tumors in vivo. The furoxan ring releases NO with the action of thiol cofactors [23]. It is hypothesized that furoxan-ring opening to give a nitroso derivative is accomplished by thiolate attacking position 3 or 4. The derivative then releases NO−, which is oxidized to release NO [35,36,37]. The ester molecules characterized by a furoxan-based NO-releasing moiety have already been explored by several research groups for improving the pharmacological profile of the parent drugs [26,38,39,40]. For example, Chen et al. synthesized a series of furoxan-based NO-releasing oleanolic acid derivatives [41]. Six derivatives exhibited strong antiproliferative activity in vitro and released high levels of NO, and two of them showed significant inhibitory activity of human hepatocellular carcinoma tumor in vivo. The hybrids with glycyrrhetinic acid were achieved by Lai et al. [42]. Five derivatives showed small IC50 values against human hepatocellular carcinoma tumor cells (0.25–1.10 μM against Bel-7402 cells and 1.32–6.78 μM against HepG 2 cells). At the same time, the selectivity between tumor and normal cells was observed, since low antiproliferative activity was obtained against the L-02 cell line. Besides, the anticancer potency of triterpenoid/furoxan-based NO-donating analogues against multidrug-resistant cancer cells was also developed by Zhang’s group [32,43]. Some furoxan-based NO donor/coumarin [40] and diterpenoid [44] hybrids were also developed as antitumor agents. So, the synthesis of natural product/NO donor derivatives is the feasible approach to get promising anticancer candidates.
The reasons above stimulated us to combine two of our molecules of interest together. So, a series of furoxan-based NO-releasing enmein-type ent-kaurane diterpenoid derivatives were developed. The antiproliferative activity of these hybrids was tested against four human cancer cell lines (Bel-7402 hepatoma, K562 leukemia, MGC-803 gastric cancer, and CaEs-17 esophageal cancer cells) and normal liver L-02 cells. The NO-releasing ability was measured by Griess assay. Then the preliminary structure activity relationship (SAR) was concluded based on these experimental data. Furthermore, the investigation of molecular mode of action and effects on apoptosis-related proteins in Bel-7402 cells was also carried out.

2. Introduction

2.1. Synthesis of Compounds 2–9 and 10a–10i

The synthesis routine is illustrated in Scheme 1. The starting material benzenethiol (2) was converted to diphenylsulfonylfuroxan (5) in a three-step sequence. Monophenylsulfonylfuroxans (6a–c) were synthesized through the reactions of 5 by treatment with corresponding diols (ethane-1,2-diol, propane-1,3-diol, and butane-1,4-diol). Finally, different anhydrides (succinic anhydride, glutaric anhydride, and phthalic anhydride) were reacted with 6a–c to obtain the key intermediate furoxan-based NO donors 7a–i [45]. Starting from commercially available ent-kaurane diterpenoid oridonin (1), enmein-type 6-oxo-6,7-seco-kaurane diterpenoid (9) was obtained by two steps of oxidation in total yields of 87% [10]. Compound 9 was reacted with furoxan-based NO donors 7a–i to produce target hybrids 10a–i.

2.2. Antiproliferative Activities in Vitro and SAR

The antiproliferative activity of 7a–i and 10a–i was evaluated using the MTT method against Bel-7402, L-02, K562, MGC-803, and CaEs-17 cell lines. The results are summarized in Table 1. Compounds 7a–i exhibited stronger antiproliferative activity against four selected tumor cell lines than in normal liver cell line L-02, with IC50 values ranging from 16.7 to 25.7 μM. Compounds 7d–f with R1 of (CH2)3 exhibited stronger cytotoxicity in tumor cells than those with R1 of (CH2)2 and (CH2)4. From these data, no obvious SAR could be concluded when R2 was changed among (CH2)2, (CH2)3, and o-C6H4. It was also found that all the target derivatives 10a–i exerted stronger antiproliferative activities than the lead oridonin against all four selected tumor cells and parent compound 9 against Bel-7402, MGC-803, and CaEs-17 cancer cell lines. In K562 cells, the IC50 values of 10a–i ranged from 1.73 to 2.90 μM, while parent compound 9 showed IC50 value of 2.64 μM. The target compounds 10 exhibited more potent cytotoxic activity than corresponding NO donors 7, which was also consistent with the literature [46]. Compounds 10a–c had the same R1 of (CH2)2, and R2 were (CH2)2, (CH2)3, and o-C6H4, respectively. Among them, 10c with R2 of o-C6H4 showed the strongest in vitro antiproliferative activity with IC50 values of 1.01, 1.97, 1.60, and 4.02 μM against Bel-7402, K562, MGC-803, and CaEs-17 cell lines, respectively. Similar SAR could also be concluded from 10d–f and 10g–i, that R2 of o-C6H4 was favorable. In general, when R2 were aromatic groups o-C6H4 (10c, 10f and 10i), the antiproliferative potency was stronger than those of alkyl groups. Compounds 10a, 10d, and 10g bearing the same R2 of (CH2)2 and 10d with R1 of (CH2)3 exhibited smaller IC50 values against the four cancer cell lines. In group 10b, 10e, and 10h, and group 10c, 10f, and 10i, similar SAR could also be observed that 10e and 10f with R1 of (CH2)3 showed stronger cytotoxic activity.
Interestingly, all the target molecules 10a–i showed selective cytotoxicity between tumor and normal liver cells, with IC50 values ranging from 22.1 to 33.9 μM against L-02 cells. Compound 10f with R1 of (CH2)3 and R2 of o-C6H4 was the most potent one against the four selected cancer cell lines. The IC50 values were 0.81, 1.73, 1.18, and 3.77 μM, which were 8.2-, 1.8-, 3.8-, 1.9-fold and 18.7-, 0.5-, 3.9-, 5.3-fold stronger than 1 and 9, respectively. The morphology effects of 10f on Bel-7402 cells are shown in Figure 2. Compound 10f also showed a good SI (selectivity index) of 36.9, while the SI values of lead oridonin and parent compound 9 were about 2.4 and 1.6, respectively. This indicated that the NO-releasing derivatives could obviously enhance the selectivity. Based on the MTT assay, most derivatives showed remarkable antiproliferative effects against Bel-7402 cells with IC50 values ranging from 0.81 to 1.91 μM. Consequently, the Bel-7402 cell line was selected for intensive mechanism studies.

2.3. NO-Releasing Ability

Exogenous release of nitric oxide by furoxan-based NO-donating enmein-type 6,7-seco-ent-kaurane diterpenoid derivatives might contribute to the cytotoxicity. The formation of nitrite (NO2−) was a reliable proxy measure for nitric oxide, in the presence of thiol. Therefore, the levels of nitrate/nitrite in the lysates of the selective hybrids 10a, 10c, and 10f were determined at 100 μM by Griess assay over the duration of 0–60 min and measured at the time points of 10, 20, 30, 40, 50, and 60 min. As shown in Figure 3, the concentration of NO increased with time, and at all the time points measured (10, 20, 30, 40, and 50 min) 10f released more NO than 10a and 10c. At the time point of 60 min, 10a, 10c, and 10f produced 22.2, 36.2, and 33.7 μmol/L of NO, respectively.

2.4. Effect of Cell Cycle

In general, anticancer agents prevented cell division at various checkpoints of cell cycle, thereby decreasing the growth and proliferation of cancerous cells. To determine whether the suppression of cell growth by furoxan-based NO donor/enmein-type 6-oxo-6,7-seco-kaurane diterpenoid hybrid 10f was caused by cell-cycle effect, we further detected the DNA content of cell nuclei by flow cytometry (Figure 4). Bel-7402 cells were treated with 10f at concentrations of 1.0, 1.5, and 2.0 μM, which resulted in accumulation of 40.27%, 48.11%, and 53.34% of cells at the S phase, respectively, compared with the untreated cells. There were almost no changes of G1 phase cells, and the decline of G2 phase cells were observed of 17.32%, 8.79%, and 6.02%, respectively. The influence of cell-cycle progression at low micromolar concentrations of NO donor/enmein-type diterpenoid hybrids would make these compounds promising agents for use in combination with anticancer drugs acting at different stages of the cell cycle.

2.5. Induction of Apoptosis

Apoptosis is a process of programmed cell death that occurs in multicellular organisms and clears the normal aging and damaged cells. However, cancer cells usually have an abnormal ability to proliferate mainly due to defective apoptosis. Thus, activation of apoptosis can be a therapeutic method for cancer by reducing accumulation of cancer cells [47]. In order to examine the involvement of apoptosis in the loss of cancer cell viability of the most potent hybrid 10f, an annexin V-FITC/propidium iodide (PI) binding assay was carried out. Bel-7402 cells were exposed to different concentrations of 10f and percentages of apoptotic Bel-7402 cells were determined by flow cytometry. As shown in Figure 5, 10f exhibited potent dose-dependent activity in the induction of apoptosis. Treatment of Bel-7402 cells with 10f at 1.0, 1.5, and 2.0 μM, apoptotic cell rates (early and late) were 23.41%, 38.32%, and 58.80%, as compared with 8.27% in an untreated vehicle control, indicating that 10f was able to induce apoptotic cell death in Bel-7402 cells in a concentration-dependent manner.

2.6. Effect of Mitochondrial Depolarization

Mitochondrial changes, including loss of mitochondrial membrane potential, were key events that took place during drug-induced apoptosis. Apoptotic signals could result in the loss of mitochondrial membrane potential in the process of apoptosis. The collapse of the mitochondrial transmembrane potential had been shown to promote mitochondrial permeability transition and induced the release of proapoptotic molecules, including apoptosis-inducing factors and cytochrome c, from the intermembrane space in the cytoplasm [48]. Subsequently, cytochrome c interacted with procaspase-9 to form the apoptosome leading to activation of caspase-9 and downstream effector caspases. The caspase-9 in turn activated the effector caspase-3 which on the other hand induced the apoptotic signaling cascade [49]. In the resent research of our group, we found cytochrome c played an important role in the lead compound oridonin 1-induced mitochondrion-mediated apoptosis [50]. To determine whether the apoptosis induced by furoxan-based NO-releasing enmein-type ent-kaurane diterpenoid derivative 10f was through mitochondrial mediated pathway, Bel-7402 cells were incubated with different concentrations (0, 0.5, 1.5, 2.0 μM) of 10f prior to staining with the lipophilic mitochondrial probe JC-1. The number of cells with collapsed mitochondrial membrane potentials in different groups of cells was determined by flow cytometry analysis (Figure 6), yielding 3.28%, 17.76%, 33.44%, and 47.63% apoptotic cells, respectively. These results demonstrated that incubation with 10f caused mitochondrial depolarization of Bel-7402 cells.

2.7. Effect of Apoptosis-Related Proteins

Caspases played an important role in the apoptotic signaling network, and apoptotic pathways depend on activation of caspases for the final execution of apoptosis. Therefore, caspase activity assay was performed to determine whether caspases were responsible for the apoptotic effects of 10f in Bel-7402 cells. Bcl-2 family proteins are important in the regulation of cell apoptosis and the pro-apoptotic protein Bax can be recruited to the mitochondrion and trigger cytochrome c release into cytoplasm to activate caspase-9 and -3 [51]. Anti-apoptotic protein Bcl-2 can inhibit the function of pro-apoptotic proteins by interaction and cancers with high levels of Bcl-2 show drug resistance in clinical cancer treatment [52]. It was found that there was upregulation of proapoptotic caspase-3, -8, -9, Bax, FAS, and cytochrome c molecules, and downregulation of anti-apoptotic Bcl-2 expression treated with 10f for 48 h in a concentration-dependent manner (Figure 7). The molecular mode of action revealed that 10f caused cell-cycle arrest of S phase and induced apoptosis in Bel-7402 cells through mitochondria-related caspase-dependent oxidative stress-triggered caspase 3-, 8-, and 9-dependent pathways.

3. Materials and Methods

3.1. Chemistry

3.1.1. General

All reagents were obtained commercially and used without further purification. Melting points were taken on an XT-4 micro melting point apparatus and uncorrected. 1H-NMR spectra were recorded with a Bruker AV-300 spectrometer (Bruker Corp., Karlsruhe, Germany) in the indicated solvents (TMS as internal standard) and 13C-NMR spectra were recorded with a Bruker AV-400 or AV-600 spectrometer (Bruker Corp.); chemical shifts were expressed as ppm against TMS as an internal reference. Splitting patterns were designed as s, singlet; d, doublet; t, triplet; m, multiplet. Mass spectra were obtained with an FTMS-2000 instrument (Thermo Fisher Scientific, Waltham, MA, USA). HRMS data were collected with an Agilent QTOF 6520 (Agilent Technologies China, Beijing, China). The reactions were monitored by thin-layer chromatography (TLC) on glass-packed precoated silica gel GF254 plates and visualized with a UV lamp. Flash column chromatography was performed using silica gel (200–300 mesh) purchased from Qingdao Haiyang Chemical Co. Ltd (Qingdao, China).

3.1.2. General Procedure to Synthesize 10

Compound 9 (72 mg, 0.2 mmol) was dissolved in 15 mL CH2Cl2 and reacted with the corresponding NO donor 7 (0.24 mmol), in addition of EDCI (0.4 mmol) and DMAP (0.02 mmol). After stirring at room temperature for 8–12 h, the mixture was poured into 15 mL 10% HCl and extracted with CH2Cl2 (3 × 10 mL). The organic layer was combined, washed sequentially with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, and concentrated in vacuo. The crude product was purified by column chromatography (MeOH/CH2Cl2 1:300 v/v) to give the title compounds. The data of compounds 10a–e and 10g–i were in Supplementary Materials.
Compound 10f: white solid, mp. 151–154 °C, yield 40%. 1H-NMR (CDCl3, 300 MHz), δ (ppm) 8.09 (2H, d, J = 7.5 Hz, Ar-H), 7.76 (2H, m, Ar-H), 7.65 (3H, m, Ar-H), 7.52 (2H, m, Ar-H), 6.24 (1H, s, 17-CH2), 5.86 (1H, s, 14-CH), 5.61 (1H, s, 17-CH2), 4.62 (1H, m, 1-CH), 4.58 (2H, m, -CH2), 4.47 (2H, m, -CH2), 4.06, 4.36 (each 1H, dd, JA = JB = 9.9 Hz, 20-CH2), 3.29 (1H, d, J = 9.0 Hz, 13-CH), 1.22 (3H, s, 18-CH3), 1.06 (3H, s, 19-CH3); 13C-NMR (CDCl3, 400 MHz) δ 197.37, 175.45, 167.21, 166.87, 166.09, 159.09, 147.03, 138.07, 135.87, 131.85, 131.69, 131.46, 130.94, 129.97, 129.93 (×2), 128.82, 128.73 (×2), 121.79, 110.70, 74.67, 71.51, 68.03, 61.34, 59.59, 50.90, 47.75, 46.31, 40.45, 36.40, 33.19, 32.36, 29.68, 27.97, 23.77, 23.21, 22.82, 19.19; MS (ESI) m/z: 808.3 [M + NH4]+, 790.9 [M + H]+, 825.1 [M + Cl]−; HRMS (ESI, M + NH4) m/z calcd for C39H42N3O14S: 808.2382, found: 808.2371.

3.2. Biology

3.2.1. MTT Assay

Cytotoxicity assay in vitro was employed by the MTT assay following the methodology described previously, which was performed in flat-bottomed 96-well plates. In short, exponentially growing MGC-803 cells at the log phase were added to each well at a density of 5 × 103 per well, then treated with serial dilutions of the compounds in three replicates at various concentrations (0.039–40 µg/mL). After 72 h, 20 µL of MTT solution (5 mg/mL) per well was added to each cultured medium. Then, DMSO was added to each well (150 µL/well). After 10 min at room temperature, the absorbance (OD) was read on a microplate reader at the wavelength of 490 nm (BIO-RAD Instruments Inc. 550, Hercules, CA, USA). In these experiments, taxol was used as the positive reference with the concentration of 10 µg/mL. The concentration causing 50% inhibition of cell growth (IC50) was determined. The same method was used in the test against L-02, CaEs-17, Bel-7402, and K562 cell lines.

3.2.2. Griess Assay

NO-releasing ability was determined by assaying the levels of NO2− using the Griess reagent. The levels of nitrate/nitrite formed from individual compounds were determined by nitrate/nitrite, in triplicate with 100 μM of individual compounds for 0–60 min according to the manufacturer’s instructions at the time points of 0, 10, 20, 30, 40, 50, and 60 min (Beyotime, Nanjing, China). The lysates were mixed with Griess reagent for 40 min and centrifugalized for 10 min, and then measured at 540 nm.

3.2.3. Cell Cycle Study

Progression through the cell cycle was assessed by flow cytometry DNA determination with PI. Bel-7402 cells were plated in 6-well plates (5.0 × 103 cells/well) and incubated at 37 °C for 24 h. Exponentially growing cells were then incubated with tested compound at a certain concentration in triplicate. Untreated cells (control) or cells treated with the solvent (DMSO) of the compound were included. After 48 h treatment, cells were centrifuged and fixed in 70% ethanol at 4 °C overnight and subsequently resuspended in PBS containing 100 μL RNase A and 400 μL PI. Cellular DNA content, for cell cycle distribution analysis, was measured using a flow cytometer (FACS Calibur Becton-Dickinson, Franklin Lake, NJ, USA).

3.2.4. Analysis of Cellular Apoptosis

The Bel-7402 cells were seeded in 6-well plates to grow overnight, and then treated with or without 10f at indicated concentrations in triplicate for 24 h. Cells were then washed twice in PBS and resuspended in annexin V binding buffer. Annexin V-FITC was then added and the mixture was incubated for 15 min under dark conditions at 25 °C. PI was added just prior to acquisition. Apoptosis was analyzed using annexin V and PI double-staining by flow cytometry according to the manufacturer’s instructions in order to detect apoptotic cells.

3.2.5. Mitochondrial Membrane Potential Assay

Briefly, Bel-7402 cells were incubated in triplicate with the test compound 10f (1.0, 1.5 and 2.0 μM) or vehicle for 48 h, and then washed with PBS and stained with JC-1 dye under dark conditions according to the manufacturer’s instruction (KeyGen Biotech, KGA601). The percentage of cells with healthy or collapsed mitochondrial membrane potentials was monitored by flow cytometry analysis.

3.2.6. Western Blot Analysis

Bel-7402 cells were incubated in triplicate with different doses (1.0, 1.5 and 2.0 μM) of 10f for 48 h. After the protein concentrations were determined, individual cell lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (10% gel, SDS-PAGE) and transferred onto nitrocellulose membranes. After being blocked with 5% fat-free milk, the target proteins in the membranes were probed with monoclonal anti-Bax (KGA714), anti-Bcl2 (KGA715), anti-caspase 3 (KGA717), anti-caspase 9 (KGA720), anti-cyto C (KGA723), and anti-β-actin antibodies (KGA731, KeyGEN Biotech, Nanjing, China), respectively. The relative levels of each signaling event to control β-actin were determined by densimetric scanning.

4. Conclusions

In this effort, a series of NO-donating/enmein-type diterpenoid hybrids 10a–i with potent antiproliferative activities was prepared. The levels of nitrate/nitrite in the cell lysates were tested by Griess assay and the results showed that the improved antiproliferative activity could be attributed to its NO releasing to some extent. The preliminary SAR of the target compounds was discussed based on the experimental data. In all the synthetic hybrids, 10f with R1 of (CH2)3 and R2 of o-C6H4 was the most potential one. The IC50 values were 0.81, 1.73, 1.18, and 3.77 μM against Bel-7402, K562, MGC-803, and CaEs-17 human cancer cells, respectively. It also showed the best cytotoxic selectivity between tumor and normal liver L-02 cells. Furthermore, the investigation concerning the molecular mode of action revealed that 10f caused cell cycle arrest of S phase and induced apoptosis in Bel-7402 cells through mitochondria-related caspase dependent pathways. It is expected that these kinds of NO-donor/diterpenoid hybrids could provide a promising approach for the discovery of novel antitumor agents.

Supplementary Materials

Supplementary materials of NMR spectrum of 10f and spectrum data of other target compounds could be found at https://0-www-mdpi-com.brum.beds.ac.uk/1420-3049/21/9/1193/s1.

Acknowledgments

This work was financially supported by the National Natural Science Foundation of China (81373280, 21502121), General Scientific Research Projects of Department of Education in Liaoning Province (L2014382), Project Funded by China Post Doctoral Science Foundation (2015M570258), Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Guangxi Normal University), Ministry of Education of China (CMEMR2015-B07) and Career Development Support Plan for Young and Middle-aged Teachers in Shenyang Pharmaceutical University.

Author Contributions

D.L., W.X., H.H. and J.X. conceived and designed the experiments; D.L., X.H., T.H., J.L., S.X. performed the experiments; D.L., J.L., Z.W. and Z.L. analyzed the data; D.L., S.X., H.H., and J.X. wrote the paper.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

The following abbreviations are used in this manuscript:
SAR
Structure Activity Relationship
1H-NMR
Proton Nuclear Magnetic Resonance
TMS
Tetramethylsilane
MS
Mass Spectrometry
ESI
Electrospray Ionization
DCM
Dichloromethane
MTT
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
FBS
Fetal Bovine Serum
NT
Not Test
FITC
Fluorescein Isothiocyanate

References

  1. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs from 1981 to 2014. J. Nat. Prod. 2016, 79, 629–661. [Google Scholar] [CrossRef] [PubMed]
  2. Sun, H.D.; Huang, S.X.; Han, Q.B. Diterpenoids from Isodon species and their biological activities. Nat. Prod. Rep. 2006, 23, 673–698. [Google Scholar] [CrossRef] [PubMed]
  3. Li, L.M.; Li, G.Y.; Pu, J.X.; Xiao, W.L.; Ding, L.S.; Sun, H.D. ent-Kaurane and cembrane diterpenoids from Isodon sculponeatus and their cytotoxicity. J. Nat. Prod. 2009, 72, 1851–1856. [Google Scholar] [CrossRef] [PubMed]
  4. He, F.; Xiao, W.L.; Pu, J.X.; Wu, Y.L.; Zhang, H.B.; Li, X.N.; Zhao, Y. Cytotoxic ent-kaurane diterpenoids from Isodon sinuolata. Phytochemistry 2009, 70, 1462–1466. [Google Scholar] [CrossRef] [PubMed]
  5. Jiang, H.Y.; Wang, W.G.; Zhou, M.; Wu, H.Y.; Zhan, R.; Li, X.N.; Du, X.; Li, Y.; Pu, J.X.; Sun, H.D. Enmein-type 6,7-seco-ent-kauranoids from Isodon sculponeatus. J. Nat. Prod. 2013, 76, 2113–2119. [Google Scholar] [CrossRef] [PubMed]
  6. Gong, J.X.; Lin, G.A.; Sun, W.B.; Li, C.C.; Yang, Z. Total synthesis of (±) maoecrystal V. J. Am. Chem. Soc. 2010, 132, 16745–16746. [Google Scholar] [CrossRef] [PubMed]
  7. Moritz, B.J.; Mack, D.J.; Tong, L.; Thomson, R. Total synthesis of the Isodon diterpene sculponeatin N. J. Angew. Chem. Int. Ed. Engl. 2014, 53, 2988–2991. [Google Scholar] [CrossRef] [PubMed]
  8. Nicolaou, K.C.; Dong, L.; Deng, L.J.; Talbot, A.C.; Chen, D.Y. Synthesis of functionalized maoecrystal V core structures. Chem. Commun. 2010, 46, 70–72. [Google Scholar] [CrossRef] [PubMed]
  9. Wang, L.; Li, D.H.; Xu, S.T.; Cai, H.; Yao, H.Q.; Zhang, Y.H.; Jiang, J.Y.; Xu, J.Y. The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: Synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents. Eur. J. Med. Chem. 2012, 52, 242–250. [Google Scholar] [CrossRef] [PubMed]
  10. Li, D.; Xu, S.; Cai, H.; Pei, L.; Wang, L.; Wu, X.; Yao, H.; Jiang, J.; Sun, Y.; Xu, J. Library construction and biological evaluation of enmein-type diterpenoid analogues as potential anticancer agents. ChemMedChem 2013, 8, 812–818. [Google Scholar] [CrossRef] [PubMed]
  11. Li, D.; Hu, X.; Han, T.; Xu, S.; Zhou, T.; Wang, Z.; Cheng, K.; Li, Z.; Hua, H.; Xiao, W.; et al. Synthesis, biological activity, and apoptotic properties of NO-donor/enmein-type ent-kauranoid hybrids. Int. J. Mol. Sci. 2016, 17, 747. [Google Scholar] [CrossRef] [PubMed]
  12. Wang, L.; Li, D.H.; Wang, C.L.; Zhang, Y.H.; Xu, J.Y. Recent progress in the development of natural ent-kaurane diterpenoids with anti-tumor activity. Mini Rev. Med. Chem. 2011, 11, 910–919. [Google Scholar] [CrossRef] [PubMed]
  13. Li, D.; Xu, S.; Cai, H.; Pei, L.; Zhang, H.; Wang, L.; Yao, H.; Wu, X.; Jiang, J.; Sun, Y.; et al. Enmein-type diterpenoid analogs from natural kaurene-type oridonin: Synthesis and their antitumor biological evaluation. Eur. J. Med. Chem. 2013, 64, 215–221. [Google Scholar] [CrossRef] [PubMed]
  14. Xu, S.; Li, D.; Pei, L.; Yao, H.; Wang, C.; Cai, H.; Yao, H.; Wu, X.; Xu, J. Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives. Bioorg. Med. Chem. Lett. 2014, 24, 2811–2814. [Google Scholar] [CrossRef] [PubMed]
  15. Xu, S.; Pei, L.; Li, D.; Yao, H.; Cai, H.; Yao, H.; Wu, X.; Xu, J. Synthesis and antimycobacterial evaluation of natural oridonin and its enmein-type derivatives. Fitoterapia 2014, 99, 300–306. [Google Scholar] [CrossRef] [PubMed]
  16. Mocellin, S. Nitric oxide: Cancer target or anticancer agent? Curr. Cancer Drug Targets 2009, 9, 214–236. [Google Scholar] [CrossRef] [PubMed]
  17. Martinez, L.; Thames, E.; Kim, J.; Chaudhuri, G.; Singh, R.; Pervin, S. Increased sensitivity of African American triple negative breast cancer cells to nitric oxide-induced mitochondria-mediated apoptosis. BMC Cancer 2016, 16, 559. [Google Scholar] [CrossRef] [PubMed]
  18. Zhan, R.; He, W.; Wang, F.; Yao, Z.; Tan, J.; Xu, R.; Zhou, J.; Wang, Y.; Li, H.; Wu, J.; et al. Nitric oxide promotes epidermal stem cell migration via cGMP-Rho GTPase signalling. Sci. Rep. 2016, 6, 30687. [Google Scholar] [CrossRef] [PubMed]
  19. Victorio, J.A.; Fontes, M.T.; Rossoni, L.V.; Davel, A.P. Different anti-contractile function and nitric oxide production of thoracic and abdominal perivascular adipose tissues. Front. Physiol. 2016, 7, 295. [Google Scholar] [CrossRef] [PubMed]
  20. Dias, C.; Lourenço, C.F.; Ferreiro, E.; Barbosa, R.M.; Laranjinha, J.; Ledo, A. Age-dependent changes in the glutamate-nitric oxide pathway in the hippocampus of the triple transgenic model of Alzheimer’s disease: Implications for neurometabolic regulation. Neurobiol. Aging 2016, 46, 84–95. [Google Scholar] [CrossRef] [PubMed]
  21. Osorio, J.C.; Recchia, F.A. The role of nitric oxide in metabolism regulation: From basic sciences to the clinical setting. Intensive Care Med. 2000, 26, 1395–1398. [Google Scholar] [CrossRef] [PubMed]
  22. Ren, Z.; Gu, X.; Lu, B.; Chen, Y.; Chen, G.; Feng, J.; Lin, J.; Zhang, Y.; Peng, H. Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells. J. Cell. Mol. Med. 2016, 20, 1095–1105. [Google Scholar] [CrossRef] [PubMed]
  23. Gazzano, E.; Chegaev, K.; Rolando, B.; Blangetti, M.; Annaratone, L.; Ghigo, D.; Fruttero, R.; Riganti, C. Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. Bioorg. Med. Chem. 2016, 24, 967–975. [Google Scholar] [CrossRef] [PubMed]
  24. Duan, W.; Hou, J.; Chu, X.; Li, X.; Zhang, J.; Li, J.; Xu, W.; Zhang, Y. Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity. Bioorg. Med. Chem. 2015, 23, 4481–4488. [Google Scholar] [CrossRef] [PubMed]
  25. Liu, L.; Wang, D.; Wang, J.; Ji, H.; Zhang, Y. NOAD, a novel nitric oxide donor, induces G2/M phase arrest and apoptosis in human hepatocellular carcinoma Bel-7402 cells. Toxicol. Vitro 2015, 29, 1289–1297. [Google Scholar] [CrossRef] [PubMed]
  26. Duan, W.; Li, J.; Inks, E.S.; Chou, C.J.; Jia, Y.; Chu, X.; Li, X.; Xu, W.; Zhang, Y. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor. J. Med. Chem. 2015, 58, 4325–4338. [Google Scholar] [CrossRef] [PubMed]
  27. Carradori, S.; Mollica, A.; de Monte, C.; Ganese, A.; Supuran, C.T. Nitric oxide donors and selective carbonic anhydrase inhibitors: A dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis. Molecules 2015, 20, 5667–5679. [Google Scholar] [CrossRef] [PubMed]
  28. Liu, L.; Li, T.; Tan, J.; Fu, J.; Guo, Q.; Ji, H.; Zhang, Y. NG as a novel nitric oxide donor induces apoptosis by increasing reactive oxygen species and inhibiting mitochondrial function in MGC803 cells. Int. Immunopharmacol. 2014, 23, 27–36. [Google Scholar] [CrossRef] [PubMed]
  29. Fang, L.; Wang, M.; Gou, S.; Liu, X.; Zhang, H.; Cao, F. Combination of amino acid/dipeptide with nitric oxide donating oleanolic acid derivatives as PepT1 targeting antitumor prodrugs. J. Med. Chem. 2014, 57, 1116–1120. [Google Scholar] [CrossRef] [PubMed]
  30. Maciag, A.E.; Holland, R.J.; Kim, Y.; Kumari, V.; Luthers, C.E.; Sehareen, W.S.; Biswas, D.; Morris, N.L.; Ji, X.; Anderson, L.M.; et al. Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells. J. Med. Chem. 2014, 57, 2292–2302. [Google Scholar] [CrossRef] [PubMed]
  31. Fu, J.; Liu, L.; Huang, Z.; Lai, Y.; Ji, H.; Peng, S.; Tian, J.; Zhang, Y. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: A glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability. J. Med. Chem. 2013, 56, 4641–4655. [Google Scholar] [CrossRef] [PubMed]
  32. Ai, Y.; Kang, F.; Huang, Z.; Xue, X.; Lai, Y.; Peng, S.; Tian, J.; Zhang, Y. Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer. J. Med. Chem. 2015, 58, 2452–2464. [Google Scholar] [CrossRef] [PubMed]
  33. Coneski, P.N.; Schoenfisch, M.H. Nitric oxide release: Part III. Measurement and reporting. Chem. Soc. Rev. 2012, 41, 3753–3758. [Google Scholar] [CrossRef] [PubMed]
  34. Huerta, S.; Chilka, B.; Bonavida, B. Nitric oxide donors: Novel cancer therapeutics (review). Int. J. Oncol. 2008, 33, 909–927. [Google Scholar] [CrossRef] [PubMed]
  35. Ferioli, R.; Folco, G.C.; Ferretti, C.; Gasco, A.M.; Medana, C.; Fruttero, R.; Civelli, M.; Gasco, A. A new class of furoxan derivatives as NO donors: Mechanism of action and biological activity. J. Pharmacol. 1995, 114, 816–820. [Google Scholar] [CrossRef]
  36. Feelisch, M.; Schönafinger, K.; Noack, E. Thiol mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem. Pharmacol. 1992, 44, 1149–1157. [Google Scholar] [CrossRef]
  37. Medana, C.; Ermondi, G.; Fruttero, R.; di Stilo, A.; Ferretti, C.; Gasco, A. Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: Thiol-mediated nitric oxide release and biological evaluation. J. Med. Chem. 1994, 37, 4412–4416. [Google Scholar] [CrossRef] [PubMed]
  38. Han, C.; Huang, Z.J.; Zheng, C.; Wan, L.D.; Zhang, L.W.; Peng, S.X.; Ding, K.; Ji, H.B.; Tian, J.D.; Zhang, Y.H. Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer. J. Med. Chem. 2013, 56, 4738–4748. [Google Scholar] [CrossRef] [PubMed]
  39. Tang, W.; Xie, J.; Xu, S.; Lv, H.; Lin, M.; Yuan, S.; Bai, J.; Hou, Q.; Yu, S. Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem. 2014, 57, 7600–7612. [Google Scholar] [CrossRef] [PubMed]
  40. Liu, M.M.; Chen, X.Y.; Huang, Y.Q.; Feng, P.; Guo, Y.L.; Yang, G.; Chen, Y. Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents. J. Med. Chem. 2014, 57, 9343–9356. [Google Scholar] [CrossRef] [PubMed]
  41. Chen, L.; Zhang, Y.; Kong, X.; Lan, E.; Huang, Z.; Peng, S.; Kaufman, D.L.; Tian, J. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid. J. Med. Chem. 2008, 51, 4834–4838. [Google Scholar] [CrossRef] [PubMed]
  42. Lai, Y.; Shen, L.; Zhang, Z.; Liu, W.; Zhang, Y.; Ji, H.; Tian, J. Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents. Bioorg. Med. Chem. Lett. 2010, 20, 6416–6420. [Google Scholar] [CrossRef] [PubMed]
  43. Tang, X.; Gu, X.; Ai, H.; Wang, G.; Peng, H.; Lai, Y.; Zhang, Y. Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells. Bioorg. Med. Chem. Lett. 2012, 22, 801–805. [Google Scholar] [CrossRef] [PubMed]
  44. Wang, T.T.; Liu, Y.; Chen, L. Synthesis and cytotoxic activity of nitric oxide-releasing isosteviol derivatives. Bioorg. Med. Chem. Lett. 2014, 24, 2202–2205. [Google Scholar] [CrossRef] [PubMed]
  45. Kelly, J.L.; McLean, E.W.; Willard, K.F. Synthesis of bis(arylsulfonyl)furoxans from aryl nitromethyl sulfones. J. Heterocycl. Chem. 1977, 14, 1415–1416. [Google Scholar] [CrossRef]
  46. Ling, Y.; Ye, X.; Zhang, Z.; Zhang, Y.; Lai, Y.; Ji, H.; Peng, S.; Tian, J. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: Synthesis and evaluation of antihepatocellular carcinoma activity. J. Med. Chem. 2011, 54, 3251–3259. [Google Scholar] [CrossRef] [PubMed]
  47. Kasibhatla, S.; Tseng, B. Why target apoptosis in cancer treatment? Mol. Cancer Ther. 2003, 2, 573–580. [Google Scholar] [PubMed]
  48. Loeffler, M.; Kroemer, G. The mitochondrion in cell death control: Certainties and incognita. Exp. Cell. Res. 2000, 256, 19–26. [Google Scholar] [CrossRef] [PubMed]
  49. Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S.M.; Ahmad, M.; Alnemri, E.S.; Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91, 479–489. [Google Scholar] [CrossRef]
  50. Xu, S.; Luo, S.; Yao, H.; Cai, H.; Miao, X.; Wu, F.; Yang, D.H.; Wu, X.; Xie, W.; Yao, H.; et al. Probing the anticancer action of oridonin with fluorescent analogues: Visualizing subcellular localization to mitochondria. J. Med. Chem. 2016, 59, 5022–5034. [Google Scholar] [CrossRef] [PubMed]
  51. Gross, A.; McDonnell, J.M.; Korsmeyer, S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999, 13, 1899–1911. [Google Scholar] [CrossRef] [PubMed]
  52. Adams, J.M.; Cory, S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998, 281, 1322–1326. [Google Scholar] [CrossRef] [PubMed]
  • Sample Availability: Samples of the compounds 10a–i are available from the authors.
Molecules 21 01193 g001 550
Figure 1. Natural enmein-type ent-kaurane diterpenoids.
Figure 1. Natural enmein-type ent-kaurane diterpenoids.
Molecules 21 01193 g001
Molecules 21 01193 sch001 550
Scheme 1. Synthesis of NO donor derivatives 10a–i. Reagents and conditions: (a) chloroactic acid, NaOH (aq), 60 °C, 4 h; (b) 30% H2O2, glacial acetic acid, rt, 2 h; (c) fuming HNO3, glacial acetic acid, 60 °C, 4 h; (d) corresponding diol, NaOH (aq), THF, rt, 2 h; (e) anhydride, DMAP/TEA, DCM, rt, 1 h; (f) sodium periodate, H2O, rt, 6 h; (g) Jones reagent, DCM, rt, 0.5 h; (h) 7a–i, EDCI, DMAP, DCM, rt, 8–12 h.
Scheme 1. Synthesis of NO donor derivatives 10a–i. Reagents and conditions: (a) chloroactic acid, NaOH (aq), 60 °C, 4 h; (b) 30% H2O2, glacial acetic acid, rt, 2 h; (c) fuming HNO3, glacial acetic acid, 60 °C, 4 h; (d) corresponding diol, NaOH (aq), THF, rt, 2 h; (e) anhydride, DMAP/TEA, DCM, rt, 1 h; (f) sodium periodate, H2O, rt, 6 h; (g) Jones reagent, DCM, rt, 0.5 h; (h) 7a–i, EDCI, DMAP, DCM, rt, 8–12 h.
Molecules 21 01193 sch001
Molecules 21 01193 g002 550
Figure 2. Morphology effects of 10f on Bel-7402 (a–e, magnification: 100 times) and L-02 cells (f–j, magnification: 40 times). Cells were treated with compound 10f for 48 h, and then observed under light microscopy. (a) Negative control; (b) solvent control (DMSO); (c) cells treated with 0.125 μM 10f, (d) cells treated with 0.5 μM 10f; (e) cells treated with 2 μM 10f; (f) negative control; (g) solvent control (DMSO); (h) cells treated with 12.5 μM 10f; (i) cells treated with 25 μM 10f; (j) cells treated with 50 μM 10f.
Figure 2. Morphology effects of 10f on Bel-7402 (a–e, magnification: 100 times) and L-02 cells (f–j, magnification: 40 times). Cells were treated with compound 10f for 48 h, and then observed under light microscopy. (a) Negative control; (b) solvent control (DMSO); (c) cells treated with 0.125 μM 10f, (d) cells treated with 0.5 μM 10f; (e) cells treated with 2 μM 10f; (f) negative control; (g) solvent control (DMSO); (h) cells treated with 12.5 μM 10f; (i) cells treated with 25 μM 10f; (j) cells treated with 50 μM 10f.
Molecules 21 01193 g002
Molecules 21 01193 g003 550
Figure 3. Griess assay of compounds 10a, 10c and 10f measured at the time points of 0, 10, 20, 30, 40, 50, and 60 min.
Figure 3. Griess assay of compounds 10a, 10c and 10f measured at the time points of 0, 10, 20, 30, 40, 50, and 60 min.
Molecules 21 01193 g003
Molecules 21 01193 g004 550
Figure 4. Influence of the cell cycle arrest of S phase by 10f in Bel-7402 cells: Bel-7402 cells were incubated with the indicated concentrations of 10f for 24 h and the cells were stained with propidium iodide (PI). Cellular DNA content, for cell cycle distribution analysis, was measured using a flow cytometer. The diagrams show the distribution of the cells according to their DNA content. The inserts give the percentages of cells in different cell cycle phases.
Figure 4. Influence of the cell cycle arrest of S phase by 10f in Bel-7402 cells: Bel-7402 cells were incubated with the indicated concentrations of 10f for 24 h and the cells were stained with propidium iodide (PI). Cellular DNA content, for cell cycle distribution analysis, was measured using a flow cytometer. The diagrams show the distribution of the cells according to their DNA content. The inserts give the percentages of cells in different cell cycle phases.
Molecules 21 01193 g004
Molecules 21 01193 g005 550
Figure 5. Apoptosis in Bel-7402 cells by treatment with 10f: Bel-7402 cells were incubated with different concentrations of 10f for 24 h and the cells were stained with annexin V-FITC and PI, followed by flow cytometry analysis.
Figure 5. Apoptosis in Bel-7402 cells by treatment with 10f: Bel-7402 cells were incubated with different concentrations of 10f for 24 h and the cells were stained with annexin V-FITC and PI, followed by flow cytometry analysis.
Molecules 21 01193 g005
Molecules 21 01193 g006 550
Figure 6. Effect of 10f on the mitochondrial membrane potentials of Bel-7402 cells: Bel-7402 cells were incubated with the indicated concentrations of 10f for 48 h prior to staining with JC-1.
Figure 6. Effect of 10f on the mitochondrial membrane potentials of Bel-7402 cells: Bel-7402 cells were incubated with the indicated concentrations of 10f for 48 h prior to staining with JC-1.
Molecules 21 01193 g006
Molecules 21 01193 g007 550
Figure 7. Western blotting of 10f on the expression of apoptosis-related proteins in Bel-7402 cells. 1: negative control; 2: 2.0 μM; 3: 1.5 μM; 4: 1.0 μM.
Figure 7. Western blotting of 10f on the expression of apoptosis-related proteins in Bel-7402 cells. 1: negative control; 2: 2.0 μM; 3: 1.5 μM; 4: 1.0 μM.
Molecules 21 01193 g007
Table
Table 1. The antiproliferative activity (IC50 a μM) of synthetic hybrids 10a–i against selected cell lines b.
Table 1. The antiproliferative activity (IC50 a μM) of synthetic hybrids 10a–i against selected cell lines b.
CompoundBel-7402L-02K562MGC-803CaEs-17
17.48 ± 0.3218.3 ± 0.84.76 ± 0.325.69 ± 0.3911.0 ± 1.0
916.0 ± 1.126.4 ± 1.32.64 ± 0.195.84 ± 0.5723.7 ± 1.8
7a22.0 ± 0.837.8 ± 1.322.6 ± 2.025.4 ± 1.524.3 ± 0.9
7b22.3 ± 1.639.6 ± 1.424.2 ± 2.522.2 ± 2.525.7 ± 1.4
7c19.6 ± 1.041.3 ± 2.922.6 ± 1.724.6 ± 1.423.8 ± 1.0
7d17.8 ± 1.437.4 ± 0.817.5 ± 1.418.5 ± 0.819.8 ± 1.3
7e18.6 ± 0.836.3 ± 2.118.5 ± 1.620.0 ± 1.118.7 ± 1.0
7f16.7 ± 0.835.8 ± 1.317.5 ± 1.019.3 ± 0.619.2 ± 0.7
7g22.7 ± 1.039.4 ± 2.624.0 ± 1.420.6 ± 1.725.7 ± 0.7
7h21.3 ± 0.735.4 ± 1.424.5 ± 1.423.5 ± 1.022.9 ± 1.4
7i22.4 ± 1.637.9 ± 2.823.0 ± 1.221.6 ± 1.524.8 ± 1.5
10a1.91 ± 0.0924.4 ± 0.82.86 ± 0.052.84 ± 1.125.68 ± 0.53
10b1.75 ± 0.1222.1 ± 1.32.90 ± 0.172.67 ± 0.245.56 ± 0.06
10c1.01 ± 0.0431.2 ± 1.21.97 ± 0.181.60 ± 0.154.02 ± 0.14
10d1.17 ± 0.0227.4 ± 1.02.04 ± 0.102.03 ± 0.154.84 ± 0.47
10e1.12 ± 0.0929.3 ± 0.92.02 ± 0.171.91 ± 0.094.04 ± 0.23
10f0.81 ± 0.0629.9 ± 1.41.73 ± 0.041.18 ± 0.103.77 ± 0.30
10g1.85 ± 0.1133.9 ± 1.52.82 ± 0.222.80 ± 0.095.52 ± 0.08
10h1.65 ± 0.1229.8 ± 0.92.78 ± 0.202.65 ± 0.165.48 ± 0.21
10i1.09 ± 0.0927.7 ± 1.32.06 ± 0.161.64 ± 0.124.13 ± 0.29
Taxol1.89 ± 0.093.73 ± 0.170.41 ± 0.024.65 ± 0.290.43 ± 0.03
a Results are expressed as mean ± S.D. of three independent experiments. b IC50: concentration that inhibits 50% of cell growth.

Share and Cite

MDPI and ACS Style

Li, D.; Hu, X.; Han, T.; Liao, J.; Xiao, W.; Xu, S.; Li, Z.; Wang, Z.; Hua, H.; Xu, J. NO-Releasing Enmein-Type Diterpenoid Derivatives with Selective Antiproliferative Activity and Effects on Apoptosis-Related Proteins. Molecules 2016, 21, 1193. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules21091193

AMA Style

Li D, Hu X, Han T, Liao J, Xiao W, Xu S, Li Z, Wang Z, Hua H, Xu J. NO-Releasing Enmein-Type Diterpenoid Derivatives with Selective Antiproliferative Activity and Effects on Apoptosis-Related Proteins. Molecules. 2016; 21(9):1193. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules21091193

Chicago/Turabian Style

Li, Dahong, Xu Hu, Tong Han, Jie Liao, Wei Xiao, Shengtao Xu, Zhanlin Li, Zhenzhong Wang, Huiming Hua, and Jinyi Xu. 2016. "NO-Releasing Enmein-Type Diterpenoid Derivatives with Selective Antiproliferative Activity and Effects on Apoptosis-Related Proteins" Molecules 21, no. 9: 1193. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules21091193

Article Metrics

Back to TopTop